Brokerages Set Bicara Therapeutics Inc. (NASDAQ:BCAX) PT at $28.33

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) have been assigned a consensus recommendation of “Moderate Buy” from the eleven analysts that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $28.3344.

BCAX has been the topic of several research reports. Citigroup started coverage on Bicara Therapeutics in a report on Thursday, January 29th. They issued an “outperform” rating on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Bicara Therapeutics in a research note on Wednesday, January 14th. UBS Group restated a “buy” rating on shares of Bicara Therapeutics in a report on Wednesday, January 14th. Wells Fargo & Company lifted their target price on Bicara Therapeutics from $8.00 to $11.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 11th. Finally, BTIG Research reaffirmed a “buy” rating on shares of Bicara Therapeutics in a research report on Thursday, January 15th.

Bicara Therapeutics Stock Up 1.5%

NASDAQ BCAX opened at $17.01 on Friday. The stock’s 50-day moving average price is $17.44 and its 200-day moving average price is $15.03. The company has a market capitalization of $931.81 million, a P/E ratio of -7.59 and a beta of -0.79. Bicara Therapeutics has a 52 week low of $7.80 and a 52 week high of $19.71.

Bicara Therapeutics (NASDAQ:BCAX) last released its earnings results on Monday, November 10th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.12). Research analysts anticipate that Bicara Therapeutics will post -2.59 EPS for the current year.

Insider Buying and Selling at Bicara Therapeutics

In other Bicara Therapeutics news, COO Ryan Cohlhepp sold 12,500 shares of the company’s stock in a transaction that occurred on Friday, November 21st. The stock was sold at an average price of $18.05, for a total value of $225,625.00. Following the sale, the chief operating officer owned 193,641 shares in the company, valued at approximately $3,495,220.05. This represents a 6.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Claire Mazumdar sold 41,163 shares of Bicara Therapeutics stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $18.86, for a total transaction of $776,334.18. Following the transaction, the chief executive officer directly owned 309,892 shares of the company’s stock, valued at approximately $5,844,563.12. This trade represents a 11.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 95,922 shares of company stock worth $1,784,142 in the last 90 days.

Hedge Funds Weigh In On Bicara Therapeutics

A number of large investors have recently bought and sold shares of BCAX. AQR Capital Management LLC acquired a new position in Bicara Therapeutics during the first quarter worth $248,000. Woodline Partners LP increased its stake in shares of Bicara Therapeutics by 26.5% during the first quarter. Woodline Partners LP now owns 348,690 shares of the company’s stock worth $4,543,000 after purchasing an additional 72,998 shares in the last quarter. TD Asset Management Inc raised its position in shares of Bicara Therapeutics by 71.5% during the 2nd quarter. TD Asset Management Inc now owns 224,538 shares of the company’s stock worth $2,086,000 after purchasing an additional 93,600 shares during the last quarter. Nan Fung Trinity HK Ltd. acquired a new position in Bicara Therapeutics in the 2nd quarter valued at $3,185,000. Finally, Geode Capital Management LLC raised its holdings in Bicara Therapeutics by 36.8% in the 2nd quarter. Geode Capital Management LLC now owns 672,485 shares of the company’s stock valued at $6,248,000 after acquiring an additional 180,833 shares during the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.